We are live on
!
Find out more
Lyell Immunopharma
LYEL
LYEL
127 hedge funds and large institutions have $297M invested in Lyell Immunopharma in 2024 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 36 increasing their positions, 44 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
77% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 13
16% more capital invested
Capital invested by funds: $256M → $297M (+$40.5M)
8% more funds holding
Funds holding: 118 → 127 (+9)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% less ownership
Funds ownership: 2.62% → 2.61% (-0%)
7% less call options, than puts
Call options by funds: $14K | Put options by funds: $15K
18% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 44
Holders
127
Holders Change
+9
Holders Change %
+7.63%
% of All Funds
1.83%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
23
Increased
36
Reduced
44
Closed
13
Calls
$14K
Puts
$15K
Net Calls
-$1K
Net Calls Change
-$1K
Top Buyers
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$7.18M |
| 2 |
Millennium Management
New York
|
+$2.44M |
| 3 |
JP Morgan Chase
New York
|
+$1.05M |
| 4 |
D.E. Shaw & Co
New York
|
+$800K |
| 5 |
Renaissance Technologies
New York
|
+$751K |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$5.76M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$3.09M |
| 3 |
Morgan Stanley
New York
|
-$1.18M |
| 4 |
HF
HRT Financial
New York
|
-$963K |
| 5 |
BlackRock
New York
|
-$877K |
